Drugs / fosbretabulin
fosbretabulin
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT03014297 | Mar 2017 → Jun 2018 | neuroendocrine neoplasm | Lowell Anthony, MD | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01052363 | Jan 2010 → ? | central nervous system neoplasm | West Virginia University | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT00395434 | Sep 2006 → Jan 2007 | neoplasm | Mateon Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00003768 | Sep 1998 → Jul 2001 | cancer of unknown primary site | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00003698 | Jul 1998 → Dec 2003 | cancer of unknown primary site | University of Glasgow | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02055690 | Sep 2014 → Nov 2017 | ovarian cancer | The Christie NHS Foundation Trust | Terminated | No outcome recorded |
| Phase 1/2 | NCT00077103 | Nov 2003 → Feb 2007 | head and neck cancer | Case Comprehensive Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01570790 | May 2003 → Jun 2005 | age-related macular degeneration, choroidal neovascularization | Johns Hopkins University | Completed | No outcome recorded |
| Phase 28 trials · 1 missed | ||||||
| Phase 2 | NCT02279602 | Dec 2014 → Aug 2016 | neuroendocrine neoplasm | Mateon Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02132468 | Sep 2014 → Jun 2016 | neuroendocrine neoplasm | Mateon Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01305213 | Mar 2011 → Aug 2016 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01023295 | Jul 2009 → Aug 2010 | perifoveal exudative vascular anomalous complex | Mateon Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00653939 | Mar 2008 → Jul 2011 | neoplasm | Mateon Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00113438 | Mar 2005 → Feb 2007 | cancer | Mateon Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01423149 | Mar 2005 → Jan 2007 | choroidal neovascularization, degenerative myopia | Mateon Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00060242 | Feb 2003 → Feb 2007 | head and neck cancer | Case Comprehensive Cancer Center | Completed | Missed primary |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT00507429 | Aug 2007 → Oct 2011 | thyroid gland undifferentiated (anaplastic) carcinoma | Mateon Therapeutics | Terminated | Missed primary Stop: Enrollment |
| Comparator or background therapy2 trials | ||||||
| Phase 2/3 | NCT02641639 Comparator | Jun 2016 → Oct 2017 | refractory malignant neoplasm | Mateon Therapeutics | Terminated | No outcome recorded |
| Phase 3 | NCT01701349 Comparator | Mar 2015 → Apr 2017 | thyroid gland undifferentiated (anaplastic) carcinoma | Mateon Therapeutics | Withdrawn | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 11
| Date | Issuer | Release |
|---|---|---|
| 2018-01-08 | Mateon Therapeutics | Results Mateon Announces New Preclinical Data Demonstrating Enhanced Tumor Immune Responses when CA4P is Given in Combination with Checkpoint Inhibitors oncotelic.com ↗
The new preclinical data also showed that the distribution of these beneficial CD8+T lymphocyte cells was observed throughout the tumor - in both the tumor rim and tumor core. |
| 2017-12-05 | Mateon Therapeutics | Results Mateon Announces Preclinical Data Indicating Enhanced Tumor Immune Response of CA4P with Checkpoint Inhibitor oncotelic.com ↗
Mateon Therapeutics, Inc . (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today announced new preliminary data in a mouse model of colon cancer indicating that reductions in tumor volume after treatment with CA4P and anti-CTLA-4 combination therapy are associated with an enhanced immune response. |
| 2017-09-26 | Mateon Therapeutics | Results Mateon Therapeutics Announces Termination of FOCUS Study in Ovarian Cancer and Restructuring to Prioritize OXi4503 for AML oncotelic.com ↗
PFS, the primary endpoint of the study, favored the CA4P group, with a 32 day increase in median PFS for the patients receiving CA4P compared to patients receiving control (202 days vs. 170 days; HR=0.844; p=0.688). |
| 2017-08-16 | Mateon Therapeutics | Results Mateon Therapeutics Announces Results from Second Interim Analysis of CA4P Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer oncotelic.com ↗
today announced results from its second scheduled interim analysis of the ongoing phase 2/3 FOCUS study evaluating CA4P in combination with bevacizumab (Avastin®) and physician's choice chemotherapy in patients with platinum resistant ovarian cancer (prOC). |
| 2017-06-28 | Mateon Therapeutics | Results Mateon Therapeutics Announces New Interim Preclinical Data on CA4P in Combination with Checkpoint Inhibitors oncotelic.com ↗
CA4P in combination with a checkpoint inhibitor significantly reduced tumor size in a CT-26 colon cancer animal model. |
| 2017-04-18 | Mateon Therapeutics | Results Mateon Therapeutics Announces Encouraging Results from First Interim Analysis of Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer oncotelic.com ↗
No significant safety issues were identified in the interim analysis, and the overall safety profile of CA4P was similar to or better than results seen in previous randomized trials of CA4P. |
| 2017-02-13 | Mateon Therapeutics | Results Mateon Therapeutics Announces Initial Pre-clinical Data on Combination of CA4P with Checkpoint Inhibitors oncotelic.com ↗
today announced encouraging preliminary data from four different syngeneic mouse models evaluating Mateon's lead investigational drug CA4P in combination with checkpoint inhibitors. |
| 2017-01-20 | Mateon Therapeutics | Results Mateon Therapeutics to Present Data on Study OX4218 in Neuroendocrine Tumors at ASCO Gastrointestinal Cancers Symposium oncotelic.com ↗
One patient (6%) experienced significant symptomatic improvement as measured by ECOG Status and had a partial response per investigator-assessed RECIST and an additional 7 patients (39%) had stable disease. |
| 2016-10-31 | Mateon Therapeutics | Results Mateon Announces Presentation of CA4P Posters at Meeting of the International Gynecologic Cancer Society oncotelic.com ↗
In the intent-to-treat population, as well as in a subgroup of patients with measurable disease, the addition of CA4P improved progression-free survival (PFS), including improvements in PFS of 6.2 months for patients with larger tumors. |
| 2016-06-20 | Mateon Therapeutics | Results UPDATE -- Mateon Therapeutics to Present New Improved Survival Outcomes for CA4P in Recurrent Ovarian Cancer at June 27 Investor Event oncotelic.com ↗
Updated data shows improvement in overall survival of 3.2 months for all CA4P-treated patients |
| 2016-06-20 | Mateon Therapeutics | Results Mateon Therapeutics to Present New Improved Survival Outcomes for CA4P in Recurrent Ovarian Cancer at June 27 Investor Event oncotelic.com ↗
Updated data shows improvement in overall survival of 3.2 months for all CA4P-treated patients |
All press releases naming this drug 15 releases
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fosbretabulin | “OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas” NCT01052363 ↗13“continue once every three weeks fosbretabulin infusions” NCT02279602 ↗ |
| Known as | CA-4DP | ChEMBL registry synonym — accepted as the source's own label CHEMBL1206232 ↗ |
| Known as | CA4P | “The purpose of the study is assess safety, bioactivity, and maximal tolerated dose of repeated weekly intravenous infusion of combretastatin A-4 phosphate (CA4P) in patients...” NCT01570790 ↗ |
| Known as | Combretastatin A4 Phosphate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00395434 ↗ |
| Known as | Fosbretabulin Combretastatin A4-Phosphate, CA4P | “Fosbretabulin Combretastatin A4-Phosphate, CA4P” NCT02641639 ↗ |
| Known as | FOSBRETABULIN DISODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL1206232 ↗ |
| Known as | Fosbretabulin disodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1206232 ↗ |
| Known as | Fosbretabulina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1206232 ↗ |
| Known as | Fosbretabuline | ChEMBL registry synonym — accepted as the source's own label CHEMBL1206232 ↗ |
| Known as | Phosbretabulin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1206232 ↗ |
| Known as | Zybrestat | ChEMBL registry synonym — accepted as the source's own label CHEMBL1206232 ↗ |
| Modality | Small molecule | — CHEMBL1206232 ↗ |
| Route | Intravenous | “weekly intravenous infusion” NCT00003698 ↗ |